Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 506197 | NSE Symbol : BLISSGVS | ISIN : INE416D01022 | Industry : Pharmaceuticals |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
21-Jan-2025	28-Jan-2025	Quarterly Results	BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/01/2025 inter alia to consider and approve The Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31 2024; and The proposal for issuance of Sweat Equity Shares pursuant to applicable provisions of the Companies Act 2013 the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations 2021 and other applicable laws and regulations to Key Managerial Personnel and/or Senior Management Personnel and/or Employee(s) of the Company including determination of the issue price if any subject to such regulatory and statutory approvals as may be required including approval of the shareholders of the Company. Please find the attached Outcome of Board Meeting held on Tuesday, January 28, 2025. (As Per Bse Announcement Dated on 28.01.2025)
17-Oct-2024	24-Oct-2024	Quarterly Results	BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/10/2024 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half yearly ended September 30 2024 Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half yearly ended September 30 2024 Please find the attached Outcome of Board Meeting held on Thursday, October 24, 2024. (As per BSE Announcement Dated on 24/10/2024)
17-Jul-2024	24-Jul-2024	Quarterly Results	BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/07/2024 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 2024. Further according to SEBI (Prohibition of Insider Trading) Regulations 2015 and the Companys Code of Internal Procedures and Conduct for Regulating Monitoring and Reporting of Trading by Designated Persons the trading window for dealing in shares of the Company was closed for all the Designated Persons and their immediate relatives of the Company from July 01 2024 and shall remain closed till 48 hours after the announcement/declaration of Unaudited Financial Results of the Company for the quarter ended June 30 2024. Please find attached herewith the Outome of Board Meeting held on today i.e. July 24, 2024 for approval of Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2024. (As per BSE Announcement Dated on 24/07/2024)
25-Apr-2024	02-May-2024	Accounts	BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/05/2024 inter alia to consider and approve a) To consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31 2024 along with the Statement of Assets and Liabilities Cash Flow Statement and take note of the Audit Report with modified opinion if any thereon; b) To consider and approve the Audited Standalone and Consolidated Financial Statement of the Company for the financial year ended March 31 2024; and c) To discuss and recommend the Final Dividend if any for the financial year ended March 31 2024. We would like to inform you that, the Board Meeting of the Company was held today i.e. Thursday, May 02, 2024 at the registered office of the Company. In pursuant to Regulation 30 and Regulation 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has considered and approved the matters amongst others as attached. Please find attached herewith Outcome of the Board Meeting held on May 02, 2024. Recommended Final Dividend of 50% i.e. 50 Paisa per equity share on the face value of Rs. 1/- each for the financial year ended March 31, 2024, subject to the approval of the shareholders in the forthcoming 39th Annual General Meeting of the Company. (As Per BSE Announcement Dated on 02.05.2024)
16-Feb-2024	16-Feb-2024	Subsidiary Company	The Board of Directors of the Company has approved an internal restruturing of foreign subsidiaries of the Company.
16-Jan-2024	23-Jan-2024	Quarterly Results	BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/01/2024 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31 2023. Further pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 and the Companys Code of Internal Procedures and Conduct for Regulating Monitoring and Reporting of Trading by Designated Persons the trading window for dealing in shares of the Company was closed for all the Designated Persons of the Company and their immediate relatives of the Company from January 01 2024 and shall remain closed until 48 hours after the announcement of Unaudited Financial Results of the Company for the quarter and nine months ended December 31 2023. Enclosed herewith the outcome of board meeting held on January 23, 2024 (As Per BSE Announcement Dated on 23.01.2024)
25-Oct-2023	01-Nov-2023	Quarterly Results	BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/11/2023 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year September 30 2023. Further pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 and the Companys Code of Internal Procedures and Conduct for Regulating Monitoring and Reporting of Trading by Designated Persons the trading window for dealing in shares of the Company was closed for all the Designated Persons of the Company and their immediate relatives of the Company from October 01 2023 and shall remain closed until 48 hours after the announcement of unaudited Financial Results of the Company for the quarter and half year September 30 2023. We would like to inform you that the Board Meeting of the Company was held today i.e. Wednesday, November 01, 2023, at the registered office of the Company. In pursuant to Regulation 30 and Regulation 33 read with Schedule III of SEBI Listing Regulations. Enclosed herewith Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2023 along with Limited Review Report. We would like to inform you that the Board Meeting of the Company was held today i.e. Wednesday, November 01, 2023, at the registered office of the Company. In pursuant to Regulation 30 and Regulation 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has considered and approved the following matters amongst others: 1. The Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2023. 2. Investment of INR 30 Crores (Approx.) for Capacity Addition/Inclusion of Semi-Solids Finished formulation at our Palghar Vevoor Unit. The Total Capacity expected is approx. 200 million Units in Semi-Solids Dosage and that is expected to be completed and available for commercial production by end of F. Y 2025-26. This expansion shall be funded by a combination of debt and internal accrual. (As per BSE Announcement Dated on 01/11/2023)
24-Jul-2023	01-Aug-2023	Quarterly Results	BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/08/2023 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 2023. Further pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 and the Companys Code of Internal Procedures and Conduct for Regulating Monitoring and Reporting of Trading by Designated Persons the trading window for dealing in shares of the Company was closed for all the Designated Persons and their immediate relatives of the Company from July 01 2023 and shall remain closed till 48 hours after the announcement/declaration of Unaudited Financial Results of the Company for the quarter ended June 30 2023. BLISS GVS PHARMA LIMITED has informed BSE about Board Meeting to be held on 01 Aug 2023 to consider financial statements for the period ended June 2023. Financial results / Other business. (As Per BSE Announcement Dated on 28.07.2023) We would like to inform you that the Board Meeting of the Company was held today i.e. Tuesday, August 01, 2023, at the registered office of the Company. In pursuant to Regulation 30 and Regulation 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has considered and approved the Unaudited standalone and consolidated financial results of the Company for the quarter ended June 30, 2023 along with the Limited Review Report and other business matters. (As Per BSE Announcement dated on 01.08.2023)
04-May-2023	11-May-2023	Accounts	BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/05/2023 inter alia to consider and approve a) To consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31 2023 along with the Statement of Assets and Liabilities Cash Flow Statement and take note of the Audit Report with modified opinion if any thereon; b) To consider and approve the Audited Standalone and Consolidated Financial Statement of the Company for the financial year ended March 31 2023; and c) To discuss and recommend the Final Dividend if any for the financial year ended March 31 2023. Board Recommended Final Dividend of 50% i.e. 0.50 paisa per equity share having face value of Rs.1/- each for the financial year ended March 31, 2023, subject to approval of the shareholders in the forthcoming 38th Annual General Meeting of the Company ('38th AGM') We would like to inform you that, the Board Meeting of the Company was held today i.e. Thursday, May 11, 2023 at the registered office of the Company. In pursuant to Regulation 30 and Regulation 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has considered and approved the matters amongst others as attached. Recommended Final Dividend of 50% i.e. 0.50 paisa per equity share having face value of Rs.1/- each for the financial year ended March 31, 2023, subject to approval of the shareholders in the forthcoming 38th Annual General Meeting of the Company ('38th AGM') (As Per BSE Announcement Dated on 11.05.2023)
17-Jan-2023	24-Jan-2023	Quarterly Results	BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/01/2023 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31 2022. Further pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 and Companys Code of Internal Procedures and Conduct for Regulating Monitoring and Reporting of Trading by Designated Persons the trading window for dealing in shares of the Company was closed for all the Designated Persons of the Company and their immediate relatives of the Company from January 01 2023 and shall remain closed until 48 hours after the announcement of unaudited Financial Results of the Company for the quarter and nine months ended December 31 2022. We would like to inform you that, Board Meeting of the Company was held today i.e. Tuesday, January 24, 2023 at the registered office of the Company. In pursuant to Regulation 30 and 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Board has considered and approved the following matter amongst others: i. The Unaudited Standalone and Consolidated Financial Results of the company for the quarter and nine months ended December 31, 2022. A copy of unaudited financial results along with the Limited Review Report of the Auditors of the Company are enclosed herewith as 'Annexure - I'. The meeting of the Board of Directors commenced at 05:30 p.m. and concluded at 08:55 p.m. (As Per BSE Announcement dated on 24.01.2023)
30-Dec-2022	30-Dec-2022	Change in Other Executives	Pursuant to Regulation 30 read with Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular CIR/CFD/CMD/4/2015 dated September 9, 2015, we wish to inform you that the Board of Directors of the Company at their meeting held today i.e. Friday, December 30, 2022 had considered and approved the Appointment of Mr. Deepak Sawant as Chief Financial Officer of the Company w.e.f. today i.e. December 30, 2022. (Disclosure pursuant to SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015 is enclosed herewith as 'Annexure-I'). Request you to kindly take the above on record and acknowledge.
29-Oct-2022	07-Nov-2022	Quarterly Results	BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2022 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year September 30 2022. Further pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 and Companys Code of Internal Procedures and Conduct for Regulating Monitoring and Reporting of Trading by Designated Persons the trading window for dealing in shares of the Company was closed for all the Designated Persons of the Company and their immediate relatives of the Company from October 01 2022 and shall remain closed until 48 hours after the announcement of unaudited Financial Results of the Company for the quarter and half year September 30 2022. We would like to inform you that, Board Meeting of the Company was held today i.e. Monday, November 07, 2022 at the registered office of the Company. In pursuant to Regulation 30 and 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Board has considered and approved the following matter amongst others: 1. The Unaudited Standalone and Consolidated Financial Results of the company for the quarter and half year ended September 30, 2022. A copy of unaudited financial results along with the Limited Review Report of the Auditors of the Company are enclosed herewith as 'Annexure - I'. The meeting of the Board of Directors commenced at 05:30 p.m. and concluded at 07:45 p.m. (As Per BSE Announcement Dated on 07.11.2022) Please find the attachment. (As per BSE Announcement Dated on 23/11/2022)
27-Jul-2022	03-Aug-2022	Quarterly Results	BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/08/2022 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 2022. Further pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 and Companys Code of Internal Procedures and Conduct for Regulating Monitoring and Reporting of Trading by Designated Persons the trading window for dealing in shares of the Company was closed for all the Designated Persons and their immediate relatives of the Company from July 01 2022 and shall remain closed till 48 hours after the announcement/declaration of Unaudited Financial Results of the Company for the quarter ended June 30 2022. We would like to inform you that, Board Meeting of the Company was held today i.e. Wednesday, August 03, 2022 at the registered office of the Company. In pursuant to Regulation 30 and 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Board has considered and approved the following matter amongst others: 1.The Unaudited Standalone and Consolidated Financial Results of the company for the quarter ended June 30, 2022. A copy of unaudited financial results along with the Limited Review Report of the Auditors of the Company are enclosed herewith as 'Annexure - I'. (As Per BSE Announcement dated on 03.08.2022)
22-Apr-2022	30-Apr-2022	Final Dividend	Final Dividend & Audited Results Bliss GVS Pharma Ltd has informed BSE that the Board Meeting of the Company will be held on April 30, 2022, inter alia, to transact the following: 1. To consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2022, along with the Statement of Assets and Liabilities, Cash Flow Statement and take note of Audit Report with modified opinion, if any, thereon. 2. To consider and approve the Audited Standalone and Consolidated Financial Statement of the Company for the financial year ended March 31, 2022 and 3. To discuss and recommend the Final Dividend, if any, for the financial year ended March 31, 2022. 1.The Audited standalone and consolidated financial results of the Company for the quarter and year ended March 31, 2022 2. Recommended Final dividend of 50% i.e. 0.50 paisa per equity share having face value of Rs.1/- each for the financial year ended March 31, 2022 3. Re-appointment of M/s. Kalyaniwalla Mistry & LLP, Chartered Accountants (Firm Registration No. 104607W/W100166), Peer Reviewed Firm as the Statutory Auditors 4. Re-appointment of M/s. BDO India LLP, Chartered Accountant having LLP registration no. AAB-7880 as Internal Auditor of the Company for the financial year 2022-23 5. Re-appointment of M/s. AVS & Associates, Practicing Company Secretaries, Peer Reviewed Firm as Secretarial Auditor of the Company for the financial year 2022-23 6. 37th AGM of the Company for the Financial Year 2021-2022 has been scheduled to be held on Tuesday, June 28, 2022 at 11:00 a.m. through Video Conferencing ('VC') / Other Audio Visual Means ('OAVM') facility (As Per BSE Announcement Dated on 02.05.2022)
21-Jan-2022	29-Jan-2022	Quarterly Results	BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/01/2022 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31 2021. Further pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 and Companys Code of Internal Procedures and Conduct for Regulating Monitoring and Reporting of Trading by Designated Persons the trading window for dealing in shares of the Company was closed for all the Designated Persons and their immediate relatives of the Company from January 01 2022 and shall remain closed till 48 hours after the announcement/declaration of Unaudited Financial Results of the Company for the quarter and nine months ended December 31 2021. This intimation is also being uploaded on the Companys website at http://www.blissgvs.com/. Kindly acknowledge and take on record the same. We would like to inform you that, Board Meeting of the Company was held today i.e. Saturday, January 29, 2022 at the registered office of the Company. In pursuant to Regulation 30 and 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Board has considered and approved the following matter amongst others: 1. The Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2021. A copy of unaudited financial results along with the Limited Review Report of the Auditors of the Company are enclosed herewith as 'Annexure - I'. (As Per BSE Announcement Dated on 29/01/2022)

1 2

LOGIN HERE

Bliss GVS Pharma Ltd

Board Meeting